Published since 1965, Laser Focus World provides comprehensive global coverage of optics, photonics, and optoelectronic technologies, applications, and markets. With 80,000+ qualified print subscribers and over a half-million annual visitors to our online content, we are the go-to source to access decision makers and stay in-the-know.

In addition to providing in-depth articles written by Laser Focus World editors, Laser Focus World accepts articles, news stories, and new product information for publication from qualified outside contributors. 

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Subscribe

A Laser Focus World newsletter subscription is free to qualified professionals. Subscribe here.

Get Published!

Laser Focus World welcomes original, bylined contributed articles for publishing, provided the material is non-commercial and runs first on our site. For consideration, contact Sally Cole Johnson ([email protected]). For more information, see our Editorial Guidelines

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics. Watch here.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community. Listen here.

Contact Us

Newsletter Archive

Magazine Archive

Meet the Laser Focus World Team

Editorial

Contact Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

GENEDX (WGS) ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin (LMT) To Contact Him Directly To Discuss Their Options

If you purchased or acquired stock in GeneDx and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of GeneDx stockholders. Our investigation concerns whether GeneDx has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On February 5, 2025, Grizzly Research ("Grizzly") published a report entitled "Insiders Attest That GeneDx (Nasdaq: WGS) Is Actively Committing Widespread Fraud". The Grizzly report asserted, among other things, that GeneDx's "growth is largely an illusion, driven by fraudulent schemes and illegal tactics deliberately aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue"; that "[t]estimonies from former employees and ongoing litigation suggest that GeneDx has inflated its revenue through an illegal practice known as ‘code stacking'", which "enables the company to bill insurance providers for services that do not meet the required criteria"; and that "CEO Katherine Stueland and CFO Kevin Feeley have consistently sold their shares immediately upon vesting, without ever engaging in open market purchases", a "pattern suggest[ing] that insiders may be aware of an imminent risk that will significantly impact the company."

On this news, GeneDx's stock price fell $4.84 per share, or 6.72%, to close at $67.18 per share on February 5, 2025.

If you purchased or otherwise acquired GeneDx shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.